The next Generation Sequencing (NGS) Service SuraSeq™ has been successfully launched in the GLP compliant Genomics Services Laboratory of the leading molecular diagnostic company, Asuragen Inc., based in Austin, Texas.
The innovative technology is helpful in the identification of de-novo mutation as well as known mutations in the tumor tissue samples obtained from specialized diagnostic techniques like FNA and FFPE. The specialized service panels like SuraSeq™ 200 and the SuraSeq™ 500 target specific molecular pathways to ascertain the activity of cancer cells. These molecular pathways include (but are not limited to) PIK3/AKT and MEK/MAP kinase pathways.
Asuragen Inc. scientists and a team of researchers have already been successful in compiling predictive, qualitative and quantitative data from the tumor tissue samples of 700 patients in a sequencing format that will help clients and other researchers in diagnostic decision making. The working technology employed for the development of SuraSeq™ 500 panel can be best explained by the validity of 2- step PCR verification discussed in a recent report published in Journal of Molecular Diagnostic.
General Manager and senior Vice President of the Texas based company, Carol Berry commented:
“Asuragen was an early adopter of NGS technology and a leader in optimizing the SuraSeq™ technology for FFPE tumor samples. We are excited to extend our proven track record of translating new technology into a robust, validated service that can be accessed by our pharmaceutical partners to identify clinically relevant and novel mutations in their targeted drug and diagnostic development programs.”
SuraScore™ can be best described as a proprietary variant caller that is capable of precise identification of mutations in the tumor tissue samples that enable researchers to compile data analysis sequencing models. Asuragen’s SuraSight™ Reporting Tool is used by the company to package the client’s data. The reporting tool allows easy browsing and exploration of data as raw files, QC metrics and summarized data.
The Cancer Prevention and Research Institute of Texas (CPRIT) partially funded the project and it is expected that the development of genomic diagnostic model will help tremendously in improving the identification of DNA mutations that will influence clinical decision making options.